3SKJ image
Deposition Date 2011-06-22
Release Date 2011-08-31
Last Version Date 2024-11-27
Entry Detail
PDB ID:
3SKJ
Keywords:
Title:
Structural And Functional Characterization of an Agonistic Anti-Human EphA2 Monoclonal Antibody
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.50 Å
R-Value Free:
0.27
R-Value Work:
0.21
R-Value Observed:
0.21
Space Group:
C 2 2 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Ephrin type-A receptor 2
Gene (Uniprot):EPHA2
Chain IDs:E, F
Chain Length:206
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Antibody, heavy chain
Chain IDs:B (auth: H), D (auth: I)
Chain Length:231
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Antibody, light chain
Chain IDs:A (auth: L), C (auth: M)
Chain Length:214
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Structural and functional characterization of an agonistic anti-human EphA2 monoclonal antibody.
J.Mol.Biol. 413 390 405 (2011)
PMID: 21867711 DOI: 10.1016/j.jmb.2011.08.018

Abstact

We report here the three-dimensional structure of human ephrin type A receptor 2 (EphA2) bound to the Fab (fragment antigen binding) of an agonistic human antibody (1C1; IgG1/κ). The structure of the corresponding complex was solved at a resolution of 2.5 Å using molecular replacement and constitutes the first reported structure of a human ephrin receptor bound to an antibody. We have also defined the corresponding functional epitope using a mutagenesis-based approach. This study revealed discrete structural features that determine the fine specificity of 1C1 to EphA2. Our data also provided a molecular basis for 1C1 mechanism of action. More precisely, we propose that its agonistic, internalizing properties are the result of ligand mimicry by the third heavy-chain complementarity-determining region of 1C1. Because EphA2 is an important contributor to cancer formation and progression, these findings may have implications for designing the next generation of anti-tumor therapies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures